Edwards Is Approved to Restart Heart Valve Trial
Edwards Lifesciences Corp. said it received U.S. regulatory approval to restart a clinical trial that would allow doctors to implant a heart valve without open-heart surgery.
Edwards said the trial used a new, simpler approach and involved a larger heart valve. The 20-patient trial is designed to test the feasibility of delivering a heart valve without surgery.
In June, Irvine-based Edwards voluntarily halted its earlier trial because the approach to the heart was too complicated and some patients died.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
